Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-788 in Healthy Adult Volunteers
NCT02255968Phase 1Terminated
- Sponsor
- Enanta Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP-788 in bacterial infection, sponsored by Enanta Pharmaceuticals. Primary endpoint: Incidence and severity of adverse events. Started Aug 2014; status: terminated.
02
Drugs
EDP-788
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02255968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255968.